Navigation Links
CryoLife to Present at Roth Capital Partners 20th Annual Orange County (OC) Growth Stock Conference
Date:2/13/2008

ATLANTA, Feb. 13 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it is scheduled to participate in the Roth Capital Partners 20th Annual OC Growth Stock Conference, February 19, 2008 at the Ritz Carlton Laguna Niguel in Dana Point, Calif.

D. Ashley Lee, executive vice president, chief operating officer and chief financial officer of CryoLife, Inc., will present Tuesday, February 19 at 8:30 a.m., Pacific Time.

CryoLife's live presentation may be accessed through its Web site, http://www.cryolife.com, on the Investor Relations page. An archived copy of the presentation will be available for 90 days on the same Web site.

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company recently received FDA clearance for its CryoValve(R) SG pulmonary human heart valves, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve, which is CE marked for distribution within the European Community.

For additional information about the Company, visit CryoLife's Web Site: http://www.cryolife.com.
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
2. CryoLife Announces Release Date and Teleconference Call Details for the Fourth Quarter and Year End 2007 Financial Results
3. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
4. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
5. CryoLife Announces Record Preservation Services and Product Revenues for 2007
6. CryoLife to Present at OneMedPlace Finance Forum
7. CryoLife to Present at 19th Annual Piper Jaffray Health Care Conference in New York
8. CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
9. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
10. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
11. CryoLife to Present at Bear Stearns Healthcare and First Albany Capitals Regenerative Technologies Conferences in New York
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 2Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 3Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 4Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 5Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 6Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 7Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 8Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 9Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 10Plate-eating good: Université de Montréal professor designs edible tableware 2Spices halt growth of breast stem cells, U-M study finds 2Osteotech Reports Third Quarter 2009 Financial Results 6039 1Osteotech Reports Third Quarter 2009 Financial Results 6039 2Osteotech Reports Third Quarter 2009 Financial Results 6039 3Osteotech Reports Third Quarter 2009 Financial Results 6039 4Osteotech Reports Third Quarter 2009 Financial Results 6039 5Osteotech Reports Third Quarter 2009 Financial Results 6039 6Osteotech Reports Third Quarter 2009 Financial Results 6039 7Osteotech Reports Third Quarter 2009 Financial Results 6039 8November 2009 story tips from the US Department of Energys Oak Ridge National Laboratory 14746 1November 2009 story tips from the US Department of Energys Oak Ridge National Laboratory 14746 2November 2009 story tips from the US Department of Energys Oak Ridge National Laboratory 14746 3Research Findings Key for Understanding Interpreting Genetic Testing for Long QT Syndrome 60803 1Research Findings Key for Understanding Interpreting Genetic Testing for Long QT Syndrome 60803 2Research Findings Key for Understanding Interpreting Genetic Testing for Long QT Syndrome 60803 3